Lacerol Retard

Diltiazem, the active ingredient in Lacerol Retard, is a calcium channel blocker (non‑dihydropyridine) presented as an oral tablet for oral use. It is employed to manage hypertension, angina pectoris and to control ventricular rate in atrial fibrillation in adult patients.

GNH USA supplies Lacerol Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diltiazem is used in cardiovascular conditions that involve elevated blood pressure, myocardial oxygen demand, or abnormal heart rhythm.

Hypertension: lowers systemic blood pressure by reducing peripheral vascular resistance. Angina pectoris: improves myocardial oxygen supply by decreasing cardiac workload and dilating coronary vessels. Rate control in atrial fibrillation: slows ventricular response through negative chronotropic effects on the atrioventricular node.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Dizziness or light‑headedness: related to blood pressure reduction. - Flushing: warm sensation, usually resolves with continued use. - Peripheral edema: swelling of ankles or lower legs. - Constipation: reduced gastrointestinal motility. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Bradycardia: markedly slow heart rate, may require medical attention. - Severe hypotension: sudden drop in blood pressure causing faintness. - AV block: impaired atrioventricular conduction, potentially life‑threatening. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: rash, itching, or anaphylaxis. - Heart failure exacerbation: worsening symptoms in susceptible patients.

Before initiating therapy, consider the following precautions.

Monitor blood pressure: check regularly during dose titration. Assess heart rate: watch for bradycardia, especially in patients with conduction disorders. Avoid in severe hepatic impairment: dose adjustment may be required. Caution with concomitant beta‑blockers: risk of excessive heart rate reduction. Pregnancy and lactation: use only if benefits outweigh risks; safety not established. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Diltiazem may interact with several medicines; review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase diltiazem plasma levels. - Co‑administration with other non‑dihydropyridine calcium channel blockers: additive negative inotropic and chronotropic effects. - Combination with beta‑blockers: heightened risk of severe bradycardia and AV block.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce diltiazem efficacy. - Digoxin: increased serum digoxin concentrations, requiring level monitoring. - Simvastatin: elevated risk of myopathy due to CYP3A4 competition.